Friendly” labels on the packaging are becoming more common in U.S. supermarkets as a growing number of Americans try obesity ...

Discontinuing obesity medicines often means the weight comes back and people lose the cardiovascular and metabolic benefits ...

MEDVi, a telehealth platform serving more than 100,000 patients, today announced an expanded physician-led program ...

Everyone's talking about weight loss drugs like Ozempic, Wegovy and Mounjaro and their implications on weight loss - but ...

Concerns about GLP-1 drugs indicated for weight loss were first raised after the FDA's Adverse Event Reporting System ...

SAN FRANCISCO -- Patients with colon cancer and comorbid obesity treated with GLP-1 receptor agonists had lower mortality and ...

Oprah Winfrey says she had one big main side effect from taking a GLP-1 weight-loss drug. The most common problems for ...

Since we know that eating less food often means getting fewer nutrients, a high-quality multivitamin acts as an insurance ...

The FDA is requesting that manufacturers of three GLP-1 receptor agonists remove information on risk for suicidal ideation ...

Novo Nordisk CEO Mike Doustdar said on Monday as many as 1.5 million patients in the U.S. may be using compounded versions of ...

Oral weight-loss drugs could account for a third or more of the overall GLP-1 market by 2030, a Novo Nordisk executive said ...

Speaking to BioSpace at the J.P. Morgan Healthcare Conference, Novartis’ chief dealmaker Ronny Gal explains why the Swiss ...